Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...
Dateline City:
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--
Merck and Endocyte Announce European CHMP Positive Opinions for
VYNFINIT® (vintafolide) and Companion Imaging
Agents FOLCEPRI® (etarfolatide) and NEOCEPRI®
(Intravenous (IV) folic acid) in Patients with Platinum-Resistant
Ovarian Cancer
Language:
English
Contact:
MerckMedia:Ian McConnell, +1 908-423-3046Claire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465Justin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292Tony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: ECYT Exchange: NASDAQ
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Folic Acid | Merck | Ovarian Cancer | Ovaries | Pharmaceuticals | Vitamin B9